Immunological Studies on Anti-Aids Drugs in ARC/AIDS

reportActive / Technical Report | Accession Number: ADB182001 | Open PDF

Abstract:

The objectives of the project were to discover and characterize immunomodulatory drugs for patients with HIV-infection and AIDS using in-vitro models and utilizing the murine LP-BM5 MAIDS model. Drugs were supplied, coded by number and were tested using those model systems. Diethyldithiocarbamate and Imexon were found to be highly active in the in-vivo system. Imexon was synergistic with AZT. Imexon in addition to activity in LP-BM5 was also active in the prevention of the development of lymphoma in the SCID mouse given human PBMC. Imexon was also found to be active against B cell malignancies in vitro. Imexon was recommended to the NIAID for development as a drug for HIV. Other compounds were found to beactive in-vitro but were not further developed because of the early termination of the project. The activity was mainly in the augmentation of mitogen responses or in the augmentation of NK activity. These included compounds 1758, 4728, and 8522. The investigator feels continued work on immunomodulation in AIDS is justified. AIDS, HTLV-III, Volunteers, Lab animals, RA I, Drug development, BD, Lymphocytes, Antiviral, Immunomodulators.

Author(s):
Hersh, Eval M.
Author Organization(s):
ARIZONA UNIV TUCSON
Descriptive Note:
Final rept. 4 Jan 1988-31 Dec 1992
Pagination:
0198

Security Markings

DOCUMENT & CONTEXTUAL SUMMARY

Distribution:
Approved For Public Release
Distribution Statement:
Approved For Public Release; Distribution Is Unlimited.

RECORD

Collection: TR
Identifying Numbers
Contract/Grant Number(s):
DAMD17-88-H-8004
Task Number(s):
AE
Project Number(s):
3M263105DH29
Monitor Series:
USAMRDC
 Subject Terms
Joint Capability Areas:
JCA_5_Command and Control; JCA_5.3_Planning; JCA_1.2.7_Experimentation; JCA_4.5.4_Requirements Definition; JCA_4.5_Operational Contract Support; JCA_1.2.3_Educating; JCA_1.2.5_Lessons Learned; JCA_4.3_Maintain; JCA_4_Logistics; JCA_5.4_Decide
Communities of Interest:
No COI(s) Identified
Descriptor(s):
*PATIENTS, *DRUGS, *HUMAN IMMUNODEFICIENCY VIRUSES, AUGMENTATION, IN VITRO ANALYSIS, RESPONSE, WORK, INFECTIOUS DISEASES, NUMBERS, IN VIVO ANALYSIS, PREVENTION, LYMPHOCYTES, ACQUIRED IMMUNE DEFICIENCY SYNDROME, LYMPHOMAS, CELLS, ADDITION, MODELS, HUMANS
Field(s)/Group(s):
Medicine and Medical Research, Microbiology
Keyword(s):
*ANTIVIRAL, DIETHYLIDITHIOCARBAMATE, IMEXON, PE62315A, WUDA315686
Report Date:
1993 Nov 01